Aldeyra Therapeutics Inc. (NASDAQ: ALDX)
$4.9400
+0.0800 ( +2.70% ) 177.8K
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Market Data
Open
$4.9400
Previous close
$4.8600
Volume
177.8K
Market cap
$290.60M
Day range
$4.6510 - $5.0250
52 week range
$2.7100 - $6.5476
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Mar 12, 2024 |
4 | Insider transactions | 1 | Mar 12, 2024 |
4 | Insider transactions | 1 | Mar 12, 2024 |
10-k | Annual reports | 89 | Mar 07, 2024 |
8-k | 8K-related | 34 | Feb 13, 2024 |
8-k | 8K-related | 13 | Jan 04, 2024 |
8-k | 8K-related | 12 | Dec 21, 2023 |
8-k | 8K-related | 33 | Dec 19, 2023 |